BioSpace News Archive

Drug Development

Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

Xencor, Inc. today announced initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML).

December 3, 2018
·
6 min read
Policy

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR

Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation (“United Therapeutics” or the “Company”) (NASDAQ: UTHR).

December 3, 2018
·
1 min read
Biotech Beach

When Good Macrophages Go Bad: New Study Reveals How Cancer Manipulates Our Immune System to Become Harder to Treat

Many factors affect cancer treatment outcome, such as the size and location of the tumor, availability of effective treatments, and timing of intervention.

December 3, 2018
·
4 min read
Cronos Group Confirms Discussions Regarding Potential Investment by Altria Group

Cronos Group Inc. today confirmed that it is engaged in discussions concerning a potential investment by Altria Group Inc. (NYSE: MO) (“Altria Group”) in Cronos Group.

December 3, 2018
·
5 min read
Drug Development

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018

Phase 1 Results of Amgen’s BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia

December 3, 2018
·
13 min read
Drug Development

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

-Data Presented in Oral Session with Simultaneous Publication in The Lancet-

December 3, 2018
·
28 min read
Drug Development

Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens

December 3, 2018
·
5 min read
BioMidwest

Heartland Dental Hosts Supported Dentists and Dental Assistants for First-Annual Implant Continuum

The Company helps supported dental professionals advance their skills in dental implants

December 3, 2018
·
2 min read
Biotech Bay

GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection

SUMMIT Study Partners Include UCL and University College London Hospitals NHS Foundation Trust in the United Kingdom, and Lung Cancer Alliance

December 3, 2018
·
5 min read
Drug Development

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson reported today updated results from Legend Biotech Inc.'s LEGEND-2 Phase 1/2 open-label study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory (R/R) multiple myeloma.

December 3, 2018
·
9 min read